Skip to main content

Table 3 Results of AGREE II appraisal for all the identified guidelines and recommendations

From: Review and evaluation of the methodological quality of the existing guidelines and recommendations for inherited neurometabolic disorders

Authors

OR

D1

D2

D3

D4

D5

D6

OQA

GR

Disorders of amino acid and other organic acid metabolism

 

Arnold GL

R

67

44

52

61

29

0

50

2

Baumgartner MR

SR

94

86

95

94

46

50

92

3

Frazier D

SR

78

92

83

97

65

58

92

2.5

Haberle J

SR

83

89

90

89

58

96

92

3

Kölker S-2011

SR

56

58

83

92

63

100

75

2.5

Kölker S-2007

R

67

36

91

89

29

100

75

2.5

NIH CDP

SR

89

86

86

81

73

4

58

2.5

Vockley J

R

89

31

60

78

48

54

75

2

Disorders of carbohydrate metabolism

 

Barba-Romero MA

R

80

61

53

83

31

50

75

2

Cochat P

R

72

28

27

92

31

33

58

2.5

Cupler EJ

R

64

64

46

67

41

63

75

2

Kishnani PS-2014

SR

86

61

47

100

58

63

75

2.5

Kishnani PS-2010

R

89

61

50

83

48

33

67

2

Kishnani PS-2006

SR

83

56

44

56

50

75

67

2

Rake JP

R

94

17

27

92

25

0

58

2

Visser G

R

83

19

23

83

23

0

50

2

Winchester B

NR

72

36

14

53

25

67

42

1.5

Disorders of vitamin and non protein cofactor metabolism and transport

 

BCMSC

R

94

31

51

61

27

0

67

2.5

Devalia V

R

83

33

71

94

67

83

83

2

Disorders of porphyrin and hem metabolism

 

Stein P

SR

89

81

56

89

56

50

75

2.5

Disorders of mineral absorption and transport

 

Bacon BR

R

56

44

75

83

46

17

67

2

BCMA

R

94

8

13

81

27

0

58

2

EASL

R

67

28

49

86

35

38

67

2

Qaseem A

NR

100

36

27

50

23

42

33

1.5

Roberts EA

R

67

17

32

78

33

0

58

2

Disorders of energy metabolism

 

Angelini

NR

64

8

36

31

8

21

33

1.5

Arnold GL

R

86

67

61

72

38

0

67

2

Finsterer J

R

75

53

48

72

19

0

58

2.5

Disorders of lysosomal and lysosomal-related organelles

 

Andersson

R

83

33

29

67

25

0

58

2.5

Bennett RL

SR

92

86

69

78

52

46

83

3

Biegstraaten M

SR

64

81

65

64

42

71

67

2

Charrow J

R

81

56

43

69

33

13

58

2

de Ru MH

SR

89

50

63

89

54

58

75

2.5

Desnick RJ

NR

64

22

40

53

48

46

42

2

Eng CM

R

92

42

45

89

46

0

67

2.5

Fahnehjelm KT

R

75

58

32

81

38

50

75

2.5

Giugliani R

R

75

56

56

67

29

38

58

2

Grabowski GA

R

72

33

27

56

33

0

50

2

Kaplan P

R

78

39

29

78

38

100

83

2

Kes VB

R

61

33

29

56

21

0

50

2

Laney DA

R

94

92

46

78

46

83

67

2.5

Langereis EJ

R

86

72

58

53

23

46

58

2

Muenzer J-2012

R

92

53

33

69

40

92

50

2.5

Muenzer J-2009

R

69

36

28

69

42

50

58

2

Ortiz A

R

58

31

40

61

23

92

50

2.5

Patterson MC

R

78

28

38

78

42

4

67

2

Peters C

NR

64

39

25

33

13

0

25

1.5

Scarpa M

SR

61

75

61

89

42

58

75

2.5

Solanki GA

R

72

39

24

61

54

100

50

1.5

Terryn W

SR

81

44

67

78

58

54

67

2.5

Vellodi A

NR

83

61

30

72

17

0

42

1.5

Vom Dahl S

R

89

36

54

56

31

83

50

2

Wang RY

SR

92

64

53

92

67

92

83

2.5

Weinreb NJ

R

67

39

30

67

17

4

50

2

Wraith JE

R

83

28

46

83

42

0

83

3

  1. OR Overall recommendation, D Domain, OQA Overall quality assessment, GR Grade of recommendation, NIH CDP National institutes of health consensus development panel, BCMSC British Columbia medical services commission, BCMA British Columbia medical association, EASL European association for study of liver, SR Strongly recommended, R Recommended, NR Not recommended domain scores were calculated as described in Methods